HC Wainwright Issues Positive Forecast for ChromaDex (NASDAQ:CDXC) Stock Price

ChromaDex (NASDAQ:CDXC) had its price objective upped by HC Wainwright from $6.00 to $8.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS and FY2025 earnings at $0.21 EPS.

ChromaDex Stock Performance

Shares of CDXC stock opened at $6.99 on Monday. The company has a market capitalization of $530.77 million, a PE ratio of 699.00 and a beta of 1.88. ChromaDex has a 52-week low of $1.32 and a 52-week high of $7.08. The business’s fifty day moving average is $3.70 and its 200 day moving average is $3.28.

ChromaDex (NASDAQ:CDXC) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The business had revenue of $25.58 million during the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same quarter in the previous year, the company earned ($0.01) EPS. On average, sell-side analysts forecast that ChromaDex will post 0.01 EPS for the current fiscal year.

Insider Transactions at ChromaDex

In other news, Director Kristin Patrick sold 23,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

Institutional investors and hedge funds have recently bought and sold shares of the business. Miracle Mile Advisors LLC purchased a new position in ChromaDex during the 2nd quarter valued at $27,000. The Manufacturers Life Insurance Company bought a new stake in shares of ChromaDex during the 2nd quarter valued at about $31,000. Merriman Wealth Management LLC purchased a new position in shares of ChromaDex during the second quarter valued at about $32,000. Lazard Asset Management LLC bought a new position in ChromaDex in the first quarter worth about $43,000. Finally, SG Americas Securities LLC purchased a new stake in ChromaDex in the first quarter worth about $54,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.